Dr. Mustafa Diken received his Ph.D. in tumor immunology from Johannes Gutenberg University, Mainz and is currently serving as the Deputy Director of Immunotherapy Development Center at TRON and Vice President of Vaccines & Immunology at BioNTech RNA Pharmaceuticals. His research focuses on the development of novel cancer and infectious disease vaccines based on antigen-encoding messenger RNA (mRNA) and the elucidation of immunomodulatory mechanisms for immunotherapy. His other scientific interests include assay development for preclinical testing of vaccines. Dr. Diken is also the scientific program director of the Association for Cancer Immunotherapy (CIMT), a non-profit organization aimed at advancing cancer immunotherapy.